MicroRNAs (miRNAs) are an abundant class of non-coding RNAs that are believed to be important in many biological processes through regulation of gene expression. The precise molecular function of miRNAs in mammals is largely unknown and a better understanding will require loss-of-function studies in vivo. Here we show that a novel class of chemically engineered oligonucleotides, termed 'antagomirs', are efficient and specific silencers of endogenous miRNAs in mice. Intravenous administration of antagomirs against miR-16, miR-122, miR-192 and miR-194 resulted in a marked reduction of corresponding miRNA levels in liver, lung, kidney, heart, intestine, fat, skin, bone marrow, muscle, ovaries and adrenals. The silencing of endogenous miRNAs by this novel method is specific, efficient and long-lasting. The biological significance of silencing miRNAs with the use of antagomirs was studied for miR-122, an abundant liver-specific miRNA. Gene expression and bioinformatic analysis of messenger RNA from antagomir-treated animals revealed that the 3' untranslated regions of upregulated genes are strongly enriched in miR-122 recognition motifs, whereas downregulated genes are depleted in these motifs. Analysis of the functional annotation of downregulated genes specifically predicted that cholesterol biosynthesis genes would be affected by miR-122, and plasma cholesterol measurements showed reduced levels in antagomir-122-treated mice. Our findings show that antagomirs are powerful tools to silence specific miRNAs in vivo and may represent a therapeutic strategy for silencing miRNAs in disease.

https://www.gene-quantification.de/kruetzfeld-antagomirs-2005.pdf

Silencing of microRNAs in vivo with ‘antagomirs’

https://cdr.lib.unc.edu/downloads/3f4627532

The Somatic Genomic Landscape of Glioblastoma

In recent years, the olefin metathesis reaction has attracted widespread attention as a versatile carbon−carbon bond-forming method. Many new applications have become possible because of major advances in catalyst design. State-of-the-art ruthenium catalysts are not only highly active but also compatible with most functional groups and easy to use. This Account traces the ideas and discoveries that were instrumental in the development of these catalysts, with particular emphasis on (PCy3)2Cl2RuCHPh and its derivatives. The discussion includes an analysis of trends in catalyst activity, a description of catalysts coordinated with N-heterocyclic carbene ligands, and an overview of ongoing work to improve the activity, stability, and selectivity of this family of L2X2RuCHR complexes.

http://web4.uwindsor.ca/users/j/jlichaa/reference.nsf/0/10ff8b04ff3a317885256d88005720f6/$FILE/acr-2001-34-18-metath-grubbs.pdf

The Development of L2X2RuCHR Olefin Metathesis Catalysts: An Organometallic Success Story

In the 10 years that have passed since the Nobel prize-winning discovery of RNA interference (RNAi), billions of dollars have been invested in the therapeutic application of gene silencing in humans. Today, there are promising data from ongoing clinical trials for the treatment of age-related macular degeneration and respiratory syncytial virus. Despite these early successes, however, the widespread use of RNAi therapeutics for disease prevention and treatment requires the development of clinically suitable, safe and effective drug delivery vehicles. Here, we provide an update on the progress of RNAi therapeutics and highlight novel synthetic materials for the encapsulation and intracellular delivery of nucleic acids.

Knocking down barriers: advances in siRNA delivery

We describe the landscape of somatic genomic alterations based on multidimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature receptors, including EGFR and PDGFRA. TERT promoter mutations are shown to correlate with elevated mRNA expression, supporting a role in telomerase reactivation. Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM. Integrative analysis of genomic and proteomic profiles challenges the notion of therapeutic inhibition of a pathway as an alternative to inhibition of the target itself. These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations and the generation of unanticipated hypotheses that can advance our molecular understanding of this lethal cancer.

The somatic genomic landscape of glioblastoma

Acide ribonucléique à double brin avec une meilleure efficacité dans un organisme

Die Erfindung betrifft ein Medikament zur Hemmung der Expression eines Zielgens, wobei das Medikament in mindestens einer Verabreichungseinheit vorliegt, welche eine mittels RNA-Interferenz zur Hemmung der Expression des Zielgens geeignete doppelstrangige Ribonukleinsaure in einer Menge enthalt, welche eine Dosierung von hochstens 5 mg pro kg Korpergewicht und Tag ermoglicht.

Medikament zur hemmung der expression eines zielgens

Ł € Oncogenes and Tumor Suppressors (795 articles)Ł € Neoplasia (4217 articles)Articles on similar topics can be found in the following Blood collectionshttp://bloodjournalhematologylibraryorg/site/misc/rightsxhtml#repub_requests Information about reproducing this article in parts or in its entirety may be found online at:http://bloodjournalhematologylibraryorg/site/misc/rightsxhtml#reprints Information about ordering reprints may be found online at:http://bloodjournalhematologylibraryorg/site/subscriptions/indexxhtml Information about subscriptions and ASH membership may be found online at:

Myeloid Differentiation of t(8;21)-positive Leukemic Cells AML1/MTG8 Oncogene Suppression by Small Interfering RNAs Supports

L'invention concerne des compositions et des methodes permettant de moduler l'expression du gene de fusion MLL-AF4 et, plus particulierement, la regulation negative de MLL-AF4 au moyen d'oligonucleotides chimiquement modifies.

Philipp Hadwiger

Papers

Acide ribonucléique à double brin avec une meilleure efficacité dans un organisme

Medikament zur hemmung der expression eines zielgens

Myeloid Differentiation of t(8;21)-positive Leukemic Cells AML1/MTG8 Oncogene Suppression by Small Interfering RNAs Supports

Modulation et utilisations de l'arni de mll-af4

Binding and Catalysis by Yeast Aldose Reductase: A Substrate‐Analogue Approach with New Aldose Derivatives.